[144] Cadrenal Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Cadrenal Therapeutics, Inc. (CVKD) notice shows an insider intends to sell 1,800 common shares, with an aggregate market value of $25,227.76, on 10/09/2025 via Merrill Lynch on NASDAQ. The shares were acquired as founders shares on 01/25/2022. The filing also discloses several recent secondary sales by the same person, totaling 15,200 shares sold across dates from 08/27/2025 to 10/02/2025 with cumulative gross proceeds of $242,044.83. The filer attests they have no undisclosed material adverse information and the form includes a standard attestation about Rule 10b5-1 plan timing if applicable.

Positive

• Planned sale fully disclosed: 1,800 shares with broker and exchange specified
• Acquisition source stated: shares identified as founders shares acquired on 01/25/2022
• Recent sales transparent: prior sales from 08/27/2025 to 10/02/2025 with itemized proceeds

Negative

• No Rule 10b5-1 adoption date provided: filing does not state a trading-plan date if one exists
• Concentration of insider selling: 15,200 shares sold in recent weeks may materially reduce insider stake

Insights

Insider Transactions Analyst

Consistent insider sales with a new proposed sale of 1,800 founder shares.

The filing shows a planned sale of 1,800 common shares valued at $25,227.76 on 10/09/2025, and prior sales by the same person totaling 15,200 shares and $242,044.83 in gross proceeds between 08/27/2025 and 10/02/2025. These prior sales are itemized with dates and proceeds, indicating active disposition of holdings.

Key dependencies include market liquidity and execution by Merrill Lynch on NASDAQ. Monitor short-term share availability and post-sale ownership disclosures for any material change in insider stake within the next days following 10/09/2025.

Corporate Governance Specialist

Filing complies with Rule 144 disclosure requirements and includes founder-acquisition detail.

The record notes the shares to be sold were acquired as founders shares on 01/25/2022, and the filer signs the standard representation about lack of undisclosed material adverse information. The document lists broker details and sale aggregation for recent transactions, which supports traceability of insider activity.

There is no information on any trading plan adoption date; if a 10b5-1 plan was used, the relevant date is not provided in the filing. Investors may watch subsequent filings for plan adoption dates or Form 4 updates in the coming weeks.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 824 A1A North Suite 200 Ponte Vedra Beach FL 32082	1800	25227.76	2046854	10/09/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/25/2022	Founders Shares	Issuer			1800	01/25/2022	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Quang X. Pham 830 A1A North Suite 196 Ponte Vedra Beach FL 32082	Common	08/27/2025	3836	53455.56
Quang X. Pham 830 A1A North Suite 196 Ponte Vedra Beach FL 32082	Common	08/28/2025	1193	16540.64
Quang X. Pham 830 A1A North Suite 196 Ponte Vedra Beach FL 32082	Common	09/24/2025	2581	36108
Quang X. Pham 830 A1A North Suite 196 Ponte Vedra Beach FL 32082	Common	09/25/2025	6790	95661.94
Quang X. Pham 830 A1A North Suite 196 Ponte Vedra Beach FL 32082	Common	09/29/2025	419	5869.5
Quang X. Pham 830 A1A North Suite 196 Ponte Vedra Beach FL 32082	Common	10/01/2025	881	12343.19
Quang X. Pham 830 A1A North Suite 196 Ponte Vedra Beach FL 32082	Common	10/02/2025	500	7066

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 for Cadrenal Therapeutics (CVKD) report?

The Form 144 reports a proposed sale of 1,800 common shares valued at $25,227.76 to occur on 10/09/2025 through Merrill Lynch on NASDAQ.

Who acquired the shares and when were they acquired?

The shares to be sold were acquired as founders shares from the issuer on 01/25/2022 and the acquisition amount listed is 1,800 shares.

What recent insider sales are disclosed in the filing?

The filing lists prior sales by Quang X. Pham totaling 15,200 shares from 08/27/2025 to 10/02/2025 with aggregate gross proceeds of $242,044.83.

Does the filing indicate a 10b5-1 trading plan adoption date?

No. The filing includes the Rule 10b5-1 attestation text but does not provide a plan adoption or instruction date.

Through which broker and exchange is the sale planned?

The planned sale is through Merrill Lynch (address provided) on the NASDAQ exchange.